Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 31, 270-273, March 1, 1971]
© 1971 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witschi, H.
Right arrow Articles by Farber, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witschi, H.
Right arrow Articles by Farber, E.

Influence of Liver Regeneration on the Loss of Fluorenylacetamide Derivative Bound to Liver DNA1

Hanspeter Witschi2, Sheldon M. Epstein3 and Emmanuel Farber4

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

N-Hydroxy-2-fluorenylacetamide-9-14C was injected i.p. into rats, and the degree of labeling of purified liver DNA was determined 16 hr later. The loss of the label from the DNA was followed subsequently over a period of 11 days. It was found that, within this period, 75% of the label was removed from the DNA. Active DNA replication, induced by partial hepatectomy, did not appear to influence the rate of removal of the 2-fluorenylacetamide derivative from the DNA in any major way.

1 Supported by research grants from the American Cancer Society and from National Institutes of Health [CA-060274 and CA-10667 from the National Cancer Institute, GM-135 (a training grant), and GM-10269 from the National Institutes of General Medical Sciences].

2 Present address: Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada.

3 Recipient of a Career Development Research Award from the National Cancer Institute (K03CA-15245).

4 Present address: Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. 19140.

Received 6/26/70. Accepted 11/16/70.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1971 by the American Association for Cancer Research.